A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients With IgAN

This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept

CT.gov Identifier
NCT07020923
EudraCT Identifier
N/A
CTIS:
2025-521519-37-00
Sponsor
Vera Therapeutics
Collaborator
N/A
Study Contact Information
+1 650 770 0077
Recruiting
Contact Us

Study Details

Diseases
Chronic Kidney Disease
IgA nephropathy
Study Drug
Atacicept
Genes
N/A
Study Dates
May 2025 - Sep 2026
Sex
Female & Male
Age
18+ years
Inclusion and Exclusion Criteria
Inclusion Criteria:
  • * Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study assessments
  • * Adult male or female of ≥18 years of age, or as per country specific legally or nationally recognized adult age, who provides written informed consent prior to performing any study assessments
  • * Diagnosis of IgAN as demonstrated by renal biopsy conducted within 10 years
  • * Total urine protein excretion ≥0.75 g per 24-hour or urine protein-to-creatinine ratio (UPCR) ≥0.75 mg/mg based on a 24-hour urine sample
  • * eGFR ≥30 mL/min/1.73 m2 at screening, as per the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
  • * On a stable prescribed regimen of RASi (angiotensin converting enzyme inhibitor or angiotensin II receptor blocker) for at least 8 weeks that is at the maximum labeled or tolerated dose at screening and from screening to study Day 1
Exclusion Criteria:
  • * IgAN secondary to another condition (eg, liver cirrhosis), or other causes of mesangial IgA deposition including IgA vasculitis (ie, Henoch-Schonlein purpura), systemic lupus erythematosus, dermatitis herpetiformis, ankylosing spondylitis
  • * Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR within 3 months of screening)
  • * Evidence of nephrotic syndrome within 6 months of screening (serum albumin <3.0 g/dL in association with UPCR >3.5 mg/mg)
  • * Renal or other organ transplantation prior to or expected during the study, with the exception of corneal transplants
  • * Concomitant chronic renal disease in addition to IgAN (eg, diabetic nephropathy, primary focal segmental glomerulosclerosis, membranous nephropathy, C3 glomerulopathy, lupus nephritis)

Protocol Summary

This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept

Study Locations

To view all trial locations, click here

Contact Us About More Information for the Clinical Trial Concierge Service

Natera’s Clinical Trial Concierge Program is comprised of a dedicated team that helps connect providers and patients with appropriate clinical trials. To learn more about a trial offered through this service, please complete the form below.  

Fields marked with asterisk (*) are mandatory.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.